Abstract 743MO
Background
Pembrolizumab plus chemotherapy +/- Bev has been approved as the 1L treatment for r/mCC patients (pts) with PD-L1 CPS ≥1. QL1706, a bifunctional Mabpair product of anti-PD-1 and anti-CTLA-4 antibodies, has shown good safety and promising efficacy in previously treated r/mCC pts in a phase Ib study. Here we report the latest efficacy and safety results from a Ph 2 study of QL1706 plus paclitaxel and cisplatin/carboplatin +/- Bev as 1L treatment of r/mCC.
Methods
In this open-label, single arm, non-randomized, phase II study, eligible pts were pathologically confirmed r/mCC and had no prior systemic treatment. Pts were treated with QL1706 (5 mg/kg, IV, D1) plus paclitaxel (175 mg/m2 or 135 mg/m2, D1) and cisplatin (50 mg/m2, D1/D2)/carboplatin (AUC = 5, D1) (cohort 1) or with Bev (15 mg/kg, D1/D2) (cohort 2) once every 3 weeks for 6 cycles. Thereafter, treatment maintained with QL1706 +/- Bev, until disease progression, intolerable toxicity, or other discontinuation events. The primary and secondary endpoints were safety and efficacy, respectively.
Results
A total of 60 pts were enrolled. As of data cutoff (Apr 24, 2023), the median follow-up time was 14.0 months. Overall 58 pts had ≥1 post baseline tumor assessment and analyzed for efficacy. The ORR was 81% (95% CI, 68.6–90.1) (8 CRs and 39 PRs). The DCR was 98.3% (95% CI, 90.8–100.0). The mPFS was 14.3 months (95% CI, 9.2-NE). The mPFS was numerically longer in cohort 2 vs cohort 1 (16.4 vs 12.5 months). The mOS was not reached. TRAEs occurred in 60 (100%) pts. The most common TRAEs (≥30% in total population) were WBC count decreased (73.3%), neutrophil count decreased (58.3%), anemia (43.3%), platelet count decreased (38.3%), and alopecia (33.3%), Grade ≥3 TRAEs occurred in 43 (71.7%) pts. Treatment-related SAEs occurred in 20 (33.3%) pts. TRAEs leading to treatment discontinuation occurred in 16 (26.7%) pts. irAEs occurred in 36 (60%) pts (Grade ≥3, 13.3%).
Conclusions
QL1706 plus platinum-based chemotherapy +/- Bev was well tolerated and showed promising antitumor activity as 1L treatment of r/mCC. Ph 3 study of QL1706 plus platinum-based chemotherapy +/- Bev as 1L treatment of r/mCC is ongoing.
Clinical trial identification
NCT05179317.
Editorial acknowledgement
Legal entity responsible for the study
Qilu Pharmaceutical Co., Ltd.
Funding
Qilu Pharmaceutical Co., Ltd.
Disclosure
X. Zhang, S. Xue, X. Kang: Other, Personal, Full or part-time Employment: Qilu Pharmaceutical. All other authors have declared no conflicts of interest.
Resources from the same session
Invited Discussant LBA45 and 746MO
Presenter: Kosei Hasegawa
Session: Mini oral session - Gynaecological cancers
Resources:
Slides
Webcast
745MO - Raludotatug deruxtecan (R-DXd; DS-6000) monotherapy in patients with previously treated ovarian cancer (OVC): Subgroup analysis of a first-in-human phase I study
Presenter: Kathleen Moore
Session: Mini oral session - Gynaecological cancers
Resources:
Abstract
Slides
Webcast
747MO - First results from the ENGOT-GYN2/GOG-3051/BOUQUET phase II biomarker-directed platform study: Cobimetinib (cobi) or atezolizumab (atezo) + bevacizumab (bev) for persistent/recurrent rare epithelial ovarian cancer (eOC)
Presenter: Isabelle Ray-Coquard
Session: Mini oral session - Gynaecological cancers
Resources:
Abstract
Slides
Webcast
Invited Discussant 745MO and 747MO
Presenter: Mansoor Raza Mirza
Session: Mini oral session - Gynaecological cancers
Resources:
Slides
Webcast